Ocrelizumab – Primary Progressive Multiple Sclerosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ocrelizumab

Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS).

Read more: http://bit.ly/1JUBLqj

Questions to Ask Your Doctor If You’re Newly Diagnosed

Illustration of doctor an patient talked
We consulted some of our community contributors at MS News Today and came up with 12 questions people should consider asking their doctors after an MS diagnosis.

Check it out by clicking here.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here